Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients

INTRODUCTION: Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resectable hepatocellular carcinoma (uHCC). This study aimed to investigate the real-world efficacy of and prognostic factors for survival associated with lenvatinib p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xu, Chen, Bowen, Wang, Yanyu, Wang, Yunchao, Long, Junyu, Zhang, Nan, Xue, Jingnan, Xun, Ziyu, Zhang, Linzhi, Cheng, Jiamin, Lei, Jin, Sun, Huishan, Li, Yiran, Lin, Jianzhen, Xie, Fucun, Wang, Dongxu, Pan, Jie, Hu, Ke, Guan, Mei, Huo, Li, Shi, Jie, Yu, Lingxiang, Zhou, Lin, Zhou, Jinxue, Lu, Zhenhui, Yang, Xiaobo, Mao, Yilei, Sang, Xinting, Lu, Yinying, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907200/
https://www.ncbi.nlm.nih.gov/pubmed/36753026
http://dx.doi.org/10.1007/s12072-022-10480-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907200/
https://www.ncbi.nlm.nih.gov/pubmed/36753026
http://dx.doi.org/10.1007/s12072-022-10480-y

Ejemplares similares